Category: cdmo

In the realm of cleanroom environments, the risk of contamination from human sources looms large, with personnel contributing to nearly 75% of the contamination. Factors such as worker behaviour, physiology, and the apparel they don play crucial roles in maintaining cleanliness and sterility within these controlled spaces. Protective apparel not only influences product quality and […]

In the realm of biopharma manufacturing, the role of contract development and manufacturing organizations (CDMOs) that provide end-to-end services is crucial for the success of sponsor companies. Christian Dowdeswell, the managing director of Arcinova, a Quotient Sciences company, sheds light on the benefits of such comprehensive services and how digital technologies are reshaping the industry […]

In the world of Contract Development and Manufacturing Organizations (CDMO), building and maintaining trusted relationships is essential for success. Thermo Fisher Scientific, a leading player in the pharmaceutical services industry, understands the importance of fostering strong partnerships with their clients. Jennifer Cannon, who leads the commercial organization for Thermo Fisher’s CDMO division, shares valuable insights […]

EirGenix Inc., a biopharmaceutical company based in Taiwan, known for its Contract Development and Manufacturing Organization (CDMO) services and independent biosimilar pipeline development, recently sealed a significant global exclusive licensing pact with Sandoz AG, a prominent player in the biosimilar market. This agreement focuses on the commercialization of EirGenix’s breast cancer biosimilar, EG1206A, a Pertuzumab […]

In a recent interview at CPHI Europe 2025, J.D. Mowery, President of Bora Pharmaceuticals, highlighted key hurdles and advancements within the biopharmaceutical industry. The conversation delved into the pressing need for global sustainability standards, the challenges of implementing artificial intelligence (AI), and the imperative for maturity in outsourcing partnerships. Mowery emphasised the critical importance of […]

In the realm of biomedical advancements, the significance of Contract Development and Manufacturing Organizations (CDMOs) cannot be overstated. These entities play a pivotal role in expediting the journey of therapeutics and medical devices from concept to market. By partnering with a CDMO, companies gain access to specialized expertise, state-of-the-art facilities, and streamlined processes that can […]

The landscape of the AI-Integrated CDMO process optimization market is evolving at a rapid pace, driven by groundbreaking advancements in peptide conjugation and tailored drug delivery systems. The insatiable demand for swift, cost-effective, and top-tier pharmaceutical development and manufacturing processes is propelling this market to new heights, promising a transformative journey towards unparalleled efficiency and […]

In an intricate dance of expertise and innovation, Indena and TCG GreenChem have orchestrated a strategic alliance to tackle the complex challenges faced by Contract Development and Manufacturing Organizations (CDMOs) on a global scale. By intertwining high-potency capabilities and green chemistry proficiency, these industry leaders are not only streamlining production processes but also setting a […]

In the evolving landscape of the medical device OEM/ODM/CDMO market, the industry is poised for substantial growth, with a projected CAGR of 7.5% to 2031. This growth is primarily driven by the increasing demand for personalized, compliant, and technologically advanced medical devices. Strategic collaborations between OEMs and service providers are redefining traditional boundaries and fostering […]

In the realm of contract development and manufacturing organizations (CDMOs), the trajectory is primed for significant growth, fueled by the expanding demand for biologics. A recent report by Jefferies analysts highlighted the optimistic outlook for CDMOs, particularly those specializing in biologics production. The projections indicate a substantial rise in the CDMO market, with an anticipated […]

The biomanufacturing landscape is facing a critical challenge as the demand for advanced biologics surges while infrastructure struggles to keep pace. This capacity squeeze is particularly evident in the production of complex modalities like monoclonal antibodies (mAbs), bispecific and multispecific antibodies (bsAbs/msAbs), and antibody-drug conjugates (ADCs) which require specialized manufacturing capabilities. The limitations in manufacturing […]

Cotec Healthcare, a prominent player in the pharmaceutical industry, has recently made waves by filing draft papers with the Securities and Exchange Board of India (SEBI) in preparation for an initial public offering (IPO). This strategic move is aimed at raising funds to further solidify its position in the market and drive growth through new […]

ST Pharm, a leading Contract Development and Manufacturing Organization (CDMO) for oligonucleotide nucleic acids, recently marked a significant milestone with the completion of its 2nd Oligo Building at the Banwol Campus in Ansan, Gyeonggi Province. This pivotal moment not only solidified ST Pharm’s position in the global market but also heralded the launch of their […]

Jubilant Ingrevia Ltd. has recently made a significant move in the pharmaceutical industry by appointing Sonia Dharap as the Vice President of Sales and Business Development based in the US. This strategic decision marks a pivotal moment for the company as Sonia brings with her over two decades of experience in the pharmaceutical sector, having […]

In September 2024, Baxter Healthcare faced a monumental challenge when the North Cove manufacturing plant was severely impacted by the flooding caused by Hurricane Helene. The aftermath of this natural disaster not only disrupted operations at the plant but also led to a nationwide shortage of crucial IV solution products. Heather Knight, the Chief Operating […]

Montagu Private Equity recently made waves in the medtech industry with its decision to rename its renowned CDMO group, consisting of Tyber Medical, Intech, and Resolve Surgical Technologies, as Exalta. This rebranding comes on the heels of the successful consolidation of these entities, marking a significant milestone in the group’s evolution and growth trajectory. The […]

Lotte Group, a prominent Korean conglomerate, has set its sights on biopharmaceuticals as a key driver of future growth, with a particular emphasis on its contract development and manufacturing organization (CDMO) arm, Lotte Biologics. At a recent topping out ceremony for Plant 1 at the Songdo Bio Campus in Incheon, Lotte Biologics underscored the strategic […]

The resurgence of the US Biosecure Act is creating ripples in the global pharmaceutical landscape, particularly for Indian contract development and manufacturing organizations (CDMOs). Nuvama Institutional Equities recently highlighted the revised draft bill, emphasizing its shift in focus from Chinese companies to a broader spectrum of entities of concern. This change, embedded within the National […]

In the realm of medical imaging, Butterfly Network has pioneered a groundbreaking approach to ultrasound technology that is revolutionizing the field. Through their innovative Ultrasound-on-Chip technology, they have successfully miniaturized ultrasound devices, making them more accessible and versatile than ever before. This shift from traditional bulky systems to compact, integrated chips has not only shrunk […]

Samsung Biologics, a leading South Korean CDMO, recently secured a monumental $1.3 billion production contract with a US-based mega pharma partner, extending until the end of 2029. This deal marks the second significant agreement for Samsung Biologics in under a year, highlighting its prowess in the contract development and manufacturing space. The identity of the […]

Piramal Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO), has collaborated with NewAmsterdam Pharma Company N.V. to inaugurate a new dedicated oral solid dosage (OSD) form suite at Piramal’s Sellersville facility in Pennsylvania, USA. This strategic move aims to bolster Piramal’s drug product capabilities by enhancing operational efficiency and expanding manufacturing services for […]

Cambrex, a prominent global contract development and manufacturing organization (CDMO), has recently augmented its peptide manufacturing capabilities through its subsidiary Snapdragon Chemistry located in Waltham, Massachusetts. This expansion aims to bolster the support for the development and production of peptide therapies within the pharmaceutical industry. The newly added GMP manufacturing suite, with an ISO-7 cleanroom, […]

In the fast-paced world of biopharmaceuticals, the role of contract development and manufacturing organizations (CDMOs) has become increasingly critical. Startups rely on them for speed to market, while established pharmaceutical companies seek scalability and precision. With patient outcomes at stake, the industry is evolving towards a new standard of operational excellence embodied by the “5F […]

PCI Pharma Services, a global CDMO specializing in innovative biopharma therapies, recently finalized the acquisition of Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO. This strategic move, part of a substantial $1 billion investment initiative, bolsters PCI’s capabilities in US drug product manufacturing, particularly in aseptic filling for prefilled syringes and cartridges. The acquisition marks […]

Regeneron Pharmaceuticals faced delays in two FDA decisions regarding the high-dose formulation of Eylea, as highlighted in the company’s Q2 report. The regulatory setbacks were attributed to manufacturing issues at Novo Nordisk-owned facilities. Originally scheduled for a decision on August 19, the FDA has now postponed its verdicts to the fourth quarter. The affected supplemental […]

A recent FDA inspection at a production facility operated by Novo Nordisk highlighted critical lapses, including pest infestations, bacterial contamination, and instrument defects. This plant, previously owned by Catalent and acquired by Novo Nordisk last year, is crucial for manufacturing therapies for companies like Regeneron and Scholar Rock. The FDA report revealed unresolved issues such […]

Three pharmaceutical companies, namely Apollo Hospitals, Abbott, and Piramal Pharma, have recently made significant moves that are catching the attention of investors and industry insiders. Suneetha Reddy, a promoter of Apollo Hospitals Enterprises, is planning to sell a portion of her shares in the company, amounting to ₹1,394.5 crore. This move is expected to impact […]

Varun Goel, the Senior Fund Manager at Mirae Asset Investment Managers (India), recently shared his insights on the current state of the Indian equity market, indicating a shift from the euphoric phase to a more realistic outlook for investors. He highlighted that the period between 2019 and 2024 was particularly robust for the Indian equity […]

The recent establishment of a 15% tariff cap on pharmaceutical imports between the US and the European Union has far-reaching implications for the pharmaceutical industry, affecting manufacturing, supply chain dynamics, and quality control protocols. This agreement, which contrasts starkly with initial proposals of much higher tariffs, is reshaping strategies for drug development, manufacturing practices, and […]

India’s CDMO and CRDMO sectors are positioned for sustained growth in FY26, with India Ratings and Research (Ind-Ra) highlighting the impact of strategic capital investments and global supply chain transformations. The report underscores how companies in these sectors are capitalizing on the trend of pharmaceutical firms diversifying their supply chain away from China, while also […]

In recent news, the court has directed the Singh Brothers to pay Rs 2,500 crore to Daiichi Sankyo, underlining the legal repercussions in the pharmaceutical sector. Intas Pharma has completed a significant acquisition of the UDENYCA biosimilar for USD 558 million, showcasing the continued investment and growth in the industry. Meanwhile, Sun Pharma and Taro […]

The U.S. mRNA therapeutics CDMO market is projected to grow significantly, reaching a valuation of $6.27 billion by 2033, driven by a CAGR of 15.01% from 2025 to 2033. The market is witnessing a shift towards diverse applications beyond pandemic responses, with a focus on new vaccines and oncology treatments. Specialized CDMOs are crucial partners […]

Esteve, a Spain-based contract development and manufacturing organization (CDMO), has recently completed the purchase of Regis Technologies, a Chicago-based CDMO, to bolster its North American footprint and advance its capabilities. The acquisition not only signifies Esteve’s expansion into the United States but also signifies its commitment to growing its CDMO services for small-molecule active pharmaceutical […]

The pharmaceutical industry heavily relies on contract development and manufacturing organizations (CDMOs) for various services, from drug development to commercial production. These CDMOs offer a wide range of solutions, including development, manufacturing, analytical testing, and regulatory filing support. Lyophilization, a critical process in pharmaceutical manufacturing, is a specialized service provided by many CDMOs to enhance […]

Contract Development and Manufacturing Organizations (CDMOs) play a pivotal role in the biotechnology and biopharmaceutical sectors, offering end-to-end services to support drug development and manufacturing processes. These services are essential for accelerating the development of advanced therapies such as cell and gene therapy. CDMOs like Cayman and Alfasigma provide trusted partnership from molecule to market, […]

In recent years, the biotech industry has witnessed a surge in Contract Development and Manufacturing Organization (CDMO) services, offering crucial support to companies in the biopharma sector. Saudi Arabia, aiming to become a global biotech hub by 2040, has launched a National Biotechnology Strategy to bolster its standing in the industry. The rise of CDMO […]

The Contract Development and Manufacturing Organizations (CDMOs) in India play a crucial role in supporting the development and manufacturing of orphan drugs. These specialized medications target rare diseases that affect a small percentage of the population. Through their expertise and infrastructure, CDMOs assist pharmaceutical companies in bringing these life-saving treatments to market efficiently and effectively. […]

LOTTE BIOLOGICS, under the leadership of CEO James Park, is making significant strides in the global Contract Development and Manufacturing Organization (CDMO) market. The company has recently completed the expansion of its Antibody-Drug Conjugate (ADC) facility at the Syracuse Bio Campus in the U.S., marking a pivotal moment in its growth trajectory. By acquiring Bristol […]